Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pomalidomide and DA-EPOCH +/- Rituximab for HIV-Associated Lymphomas
NCT05389423Phase 1Recruiting
- Sponsor
- National Cancer Institute
- Start
- Jun 2023
- Primary completion
- Jun 2028
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
Phase 1, open-label trial of pomalidomide in non-Hodgkin lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL) and 1 more (2 arms), sponsored by National Cancer Institute. Primary endpoint: Safety and Tolerability. Started Jun 2023; status: recruiting.
02
Drugs
pomalidomide
03
Conditions
non-Hodgkin lymphoma (NHL)diffuse large B-cell lymphoma (DLBCL)Burkitt lymphoma (BL)plasmablastic lymphoma (PBL)
Beyond the preview
Go deeper on NCT05389423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05389423.